EvoTears® OMEGA - EvoTears®
Novaliq: Transforming Tears (OIS@AAO 2016) - YouTube
Novaliq completes enrollment in second Phase 3 study of candidate to treat dry eye
CyclASol - Novaliq
OVERCOMING THE CHALLENGES OF OPHTHALMIC DELIVERY USING AQUEOUS-FREE TECHNOLOGY: REDEFINING DRY EYE DISEASE
Products - Novaliq
Novaliq GmbH: Geuder AG
Products - Novaliq
Management - Novaliq
Disease Areas & Pipeline - Novaliq
Anterior Segment Company Showcase - Novaliq GmbH
Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease | Business Wire
Startseite - Novaliq
Anterior Segment Company Showcase - Novaliq GmbH
Press Releases - Novaliq
Investor Relation - Novaliq
NOVALIQ PRESENTS DATA FROM SECOND PHASE 3 TRIAL OF INVESTIGATIONAL TREATMENT CYCLASOL® (0.1% CYCLOSPORINE OPHTHALMIC SOLUTION) AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING
Novaliq GmbH: Geuder AG
Anterior Segment Company Showcase - Novaliq GmbH
Anterior Segment Company Showcase - Novaliq GmbH
Products - Novaliq
Novaliq eyes dermatology opportunity, spinning off 3 programs and securing $15M for clinical trials | Fierce Pharma
Anterior Segment Company Showcase - Novaliq GmbH
Novaliq schließt Rekrutierung der zweiten Phase III-Studie für CyclASol® zur Behandlung von Trockenes Auge (Keratoconjunctivitis sicca - „KCS", oder auch Syndrom des trockenen Auges) ab
